MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma

NCT03773744 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped insufficient suitable drug supply

Conditions

Metastatic Melanoma
Squamous Cell Skin Carcinoma

Interventions

DRUG: Ad-MAGEA3
DRUG: MG1-MAGEA3
DRUG: Pembrolizumab
DRUG: Cyclophosphamide

Sponsor

Turnstone Biologics, Corp.